| Clinical data | |
|---|---|
| Other names | ALT-801; MD-1373; SP-1373 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| Chemical and physical data | |
| Formula | C182H275N39O54 |
| Molar mass | 3873.421 g·mol−1 |
Pemvidutide (ALT-801) is an experimental dual GLP-1/glucagon receptor agonist developed by Altimmune.[1][2] The drug reduced LDL-C in a clinical trial[3] and does not require dose titration as with GLP-1 mono agonists.[4]
References
- ↑ Beaney, Abigail (30 June 2023). "Obesity: Six trials to watch over the next 12 months". Clinical Trials Arena. Retrieved 5 December 2023.
- ↑ Bailey, Clifford J.; Flatt, Peter R.; Conlon, J. Michael (March 2023). "An update on peptide-based therapies for type 2 diabetes and obesity". Peptides. 161: 170939. doi:10.1016/j.peptides.2023.170939.
- ↑ Plutzky, Jorge; Harris, M. Scott S; Alonso, Cristina; Suschak, John; Noor, Mustafa; Ortiz, Pablo; Georges, Bertrand; Rader, Daniel J; Roberts, Scot S; Browne, Sarah K (8 November 2022). "Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators". Circulation. 146 (Suppl_1). doi:10.1161/circ.146.suppl_1.13440.
- ↑ Klein, Samuel; Nestor, John J.; Harris, M. Scott; Suyundikov, Anvar; Casper, Rob; Steele, Staci M.; Payne, Jacques D.; Krishnan, Vyjayanthi; Roberts, M. Scot; Browne, Sarah K. (1 June 2022). "334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity". Diabetes. 71 (Supplement_1). doi:10.2337/db22-334-OR.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.